Regenxbio selloff ‘an overreaction’ to clinical hold, says Leerink

6 days ago 6

TipRanks

Thu, January 29, 2026 astatine 9:10 AM CST 1 min read

After Regenxbio (RGNX) disclosed the FDA enactment a objective clasp connected RGX-111 for Hurler syndrome and connected the RGX-121 survey for Hunter syndrome, Leerink said the astir 30% premarket selloff successful shares underscores the grade of astonishment connected the news, feeding into the “FDA unpredictability” constituent of the carnivore thesis crossed cistron therapy. However, the steadfast views this pullback arsenic “an overreaction” based connected the humble fiscal publication of Hunter/Hurler to the cardinal worth of shares and views this arsenic a buying opportunity, says the analyst, who has an Outperform standing connected Regenxbio shares.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected RGNX:

Disclaimer & DisclosureReport an Issue

Regenxbio objective clasp does not alteration thesis, says Clear Street
FDA Halts RegenXBio MPS Gene Therapy Trials
Regenxbio announces FDA places objective clasp connected RGX-111
Regenxbio down 35% to $8.59 aft FDA places objective clasp connected RGX-111
Regenxbio announces FDA places objective clasp of RGX-111

Read Entire Article